Front Endocrinol (Lausanne) August 2024 PMID 39114288

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.

Qiyuan Keith Liu

Download social card

Mentions

8
Peak: 5 in Jul 2024
across 2 sources since Jul 2024

Extended reach

75,952
potential audience

Total likes

670

Video views

37,281

Mentions per month

Jul 2024 – Nov 2025

Where it's discussed

  • X / Twitter5 posts
  • YouTube3 videos

AI synopsis

What people are saying

The discussions highlight the importance of GLP-1 and GIP mechanisms, with posts emphasizing the therapeutic potential, such as 'new research' and 'clinical applications.' The tone suggests excitement about advancements in treatment options, and words like 'mechanisms,' 'applications,' and 'therapeutic' convey a focus on scientific progress and potential impact.

AgreementModerate agreement

Most discussions acknowledge the significance of the research, with some expressing strong support for its clinical relevance.

InterestHigh interest

The majority of comments show high curiosity and enthusiasm for the topic, especially regarding new therapies for diabetes and obesity.

EngagementModerate engagement

Posts often reference the mechanisms and potential applications, indicating moderate depth of engagement rather than superficial mentions.

ImpactModerate impact

Participants seem to believe the research could have meaningful implications for future medical treatments.

Abstract in brief

  • The text explains that GIP and GLP1 are hormones called incretins that regulate blood sugar, appetite, and fat storage, playing key roles in energy balance and metabolic health.
  • GIP and GLP1 have different effects on glucagon production depending on blood sugar levels, with GIP increasing glucagon during hypoglycemia and GLP1 suppressing it during hyperglycemia, which helps maintain blood sugar stability.
  • Pharmaceuticals targeting these hormones, especially GLP1 and dual GIP/GLP1 receptor agonists, are used to treat type 2 diabetes and obesity by improving insulin response, aiding weight management, and reducing cardiovascular risks.

Top posts

Most liked on X and Bluesky
Frontiers - Endocrinology
@FrontEndocrinol · X

New Research: Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists https://t.co/7GUvu2CS17 #FrontiersIn #Endocrinology

Jul 24, 2024 · 4 likes · 1 share · 5,050 followers View post →
The Heart
@ZHeart11768530 · X

Jul 31, 2024 · 3 likes · 2 shares · 32,781 followers View post →
Sintayehu Abebe
@sinta_gf · X

RT @ZHeart11768530:

Jul 31, 2024 · 2 shares · 452 followers View post →
Zaheer Bayat
@ZaheerBayat786 · X

RT @FrontEndocrinol: New Research: Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists https://…

Jul 24, 2024 · 1 share · 282 followers View post →

All mentions

Sintayehu Abebe
@sinta_gf · X

RT @ZHeart11768530:

Jul 31, 2024 · 2 shares · 452 followers View post →
Juan Manuel Núñez
@Juanma_JMNC · X

RT @ZHeart11768530:

Jul 31, 2024 · 2 shares · 91 followers View post →
The Heart
@ZHeart11768530 · X

Jul 31, 2024 · 3 likes · 2 shares · 32,781 followers View post →
Zaheer Bayat
@ZaheerBayat786 · X

RT @FrontEndocrinol: New Research: Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists https://…

Jul 24, 2024 · 1 share · 282 followers View post →
Frontiers - Endocrinology
@FrontEndocrinol · X

New Research: Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists https://t.co/7GUvu2CS17 #FrontiersIn #Endocrinology

Jul 24, 2024 · 4 likes · 1 share · 5,050 followers View post →